Show simple item record

dc.contributor.authorMa, Joyce HY
dc.contributor.authorWu, Albert
dc.contributor.authorVeness, Michael
dc.contributor.authorEstall, Vanessa
dc.contributor.authorHong, Angela
dc.contributor.authorBorg, Martin
dc.contributor.authorJames, Craig
dc.contributor.authorIbbetson, Jan
dc.contributor.authorOoi, Colin
dc.contributor.authorWeightman, Warren
dc.contributor.authorMcColl, Ian
dc.contributor.authorHamann, Ian
dc.contributor.authorGrieve, Noel
dc.contributor.authorOzluer, Selim
dc.contributor.authoret al.
dc.date.accessioned2021-09-22T05:53:26Z
dc.date.available2021-09-22T05:53:26Z
dc.date.issued2016
dc.identifier.issn1076-0512
dc.identifier.doi10.1097/DSS.0000000000000864
dc.identifier.urihttp://hdl.handle.net/10072/408211
dc.description.abstractBackground: In-transit metastasis from cutaneous squamous cell carcinoma (SCC) is an uncommon form of metastasis through lymphatics and occurs more commonly in immunosuppressed patients. Objective: To identify cases of in-transit SCC and determine patient characteristics, tumor features, management, and prognosis. Methods and materials: A multicenter case series treated by Australian and New Zealand clinicians. Results: In 31 patients, median age was 72 years (range 52-99) and 68% were immunocompetent. Tumors occurred on the head and neck in 94% of cases, with 71% of all tumors occurring on the scalp, forehead, or temple. The median time to presentation with in-transit SCC from treatment of the initial tumor was 5 months. Management included surgery (94%), radiotherapy (77%), chemotherapy (10%), and reduction of immunosuppression (3%). Median follow-up was 12 months. Overall survival at 3 and 5 years were 27% and 13%, respectively. Conclusion: In-transit metastases are described in 31 patients, of whom the majority was immunocompetent. The scalp, forehead, and temple were the most common sites. New clinical and histological diagnostic criteria are proposed. Prognosis was poor with 5-year survival of 13%. Recommended management is a combination of surgery and adjuvant radiotherapy. Reduction of any iatrogenic immunosuppression should be considered.
dc.description.peerreviewedYes
dc.languageEnglish
dc.publisherWolters Kluwer Health
dc.relation.ispartofpagefrom1285
dc.relation.ispartofpageto1292
dc.relation.ispartofissue11
dc.relation.ispartofjournalDermatologic Surgery
dc.relation.ispartofvolume42
dc.subject.fieldofresearchClinical sciences
dc.subject.fieldofresearchcode3202
dc.subject.keywordsScience & Technology
dc.subject.keywordsLife Sciences & Biomedicine
dc.subject.keywordsDermatology
dc.subject.keywordsSurgery
dc.subject.keywordsCERVICAL LYMPH-NODES
dc.titleIn-transit metastasis from squamous cell carcinoma
dc.typeJournal article
dc.type.descriptionC1 - Articles
dcterms.bibliographicCitationMa, JHY; Wu, A; Veness, M; Estall, V; Hong, A; Borg, M; James, C; Ibbetson, J; Ooi, C; Weightman, W; McColl, I; Hamann, I; Grieve, N; Ozluer, S; et al., In-transit metastasis from squamous cell carcinoma, Dermatologic Surgery, 2016, 42 (11), pp. 1285-1292
dc.date.updated2021-09-22T05:50:11Z
gro.hasfulltextNo Full Text
gro.griffith.authorOzluer, Selim M.


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

  • Journal articles
    Contains articles published by Griffith authors in scholarly journals.

Show simple item record